Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia

[1]  S. Snyder,et al.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. , 1976, The American journal of psychiatry.

[2]  Shirley Hansen,et al.  γ-AMINOBUTYRIC-ACID DEFICIENCY IN BRAIN OF SCHIZOPHRENIC PATIENTS , 1979, The Lancet.

[3]  J. Coyle,et al.  Methylazoxymethanol treatment of fetal rats results in abnormally dense noradrenergic innervation of neocortex. , 1979, Science.

[4]  M. Taylor.  Epilepsy and Psychiatry , 1983 .

[5]  J. Bird.  Computed Tomographic Brain Studies and Treatment Response in Schizophrenia , 1985, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[6]  E. G. Jones,et al.  Reduction in number of immunostained GABAergic neurones in deprived-eye dominance columns of monkey area 17 , 1986, Nature.

[7]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[8]  J. Deakin,et al.  Reduced GABA uptake sites in the temporal lobe in schizophrenia , 1989, Neuroscience Letters.

[9]  T. Svensson,et al.  Phencyclidine activates rat A10 dopamine neurons but reduces burst activity and causes regularization of firing. , 1990, Acta physiologica Scandinavica.

[10]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[11]  A. Grace.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[12]  F. Benes,et al.  Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. , 1991, Archives of general psychiatry.

[13]  R. Gur,et al.  Neuropsychological function in schizophrenia. Selective impairment in memory and learning. , 1991, Archives of general psychiatry.

[14]  S. Andrews,et al.  Mismatch negativity: An index of a preattentive processing deficit in schizophrenia , 1991, Biological Psychiatry.

[15]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[16]  Karl J. Friston,et al.  The left medial temporal region and schizophrenia. A PET study. , 1992, Brain : a journal of neurology.

[17]  R. S. Jones,et al.  Basket-like interneurones in layer II of the entorhinal cortex exhibit a powerful NMDA-mediated synaptic excitation , 1993, Neuroscience Letters.

[18]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[19]  W Ritter,et al.  Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. , 1995, Archives of general psychiatry.

[20]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[21]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[22]  P. Goldman-Rakic.  Cellular basis of working memory , 1995, Neuron.

[23]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[24]  C. Schroeder,et al.  Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Hasselmo,et al.  NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  P. Somogyi,et al.  Physiological properties of anatomically identified basket and bistratified cells in the CA1 area of the rat hippocampus in vitro , 1996, Hippocampus.

[28]  J. Leon.  Smoking and Vulnerability for Schizophrenia , 1996 .

[29]  F. Benes,et al.  Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain , 1996, Synapse.

[30]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[31]  T. Woo,et al.  Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. , 1997, The American journal of psychiatry.

[32]  J. Neale,et al.  N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells , 1997, Journal of neurochemistry.

[33]  L. Role,et al.  A Cysteine-Rich Isoform of Neuregulin Controls the Level of Expression of Neuronal Nicotinic Receptor Channels during Synaptogenesis , 1998, Neuron.

[34]  T. Woo,et al.  A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Alpert,et al.  Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.

[36]  O. Paulsen,et al.  Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro , 1998, Nature.

[37]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[38]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[39]  P. McKenna,et al.  Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression , 1999, Neuroscience.

[40]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[41]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[42]  A. Sampson,et al.  Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.

[43]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[44]  Yogesh K. Dwivedi,et al.  Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. , 2000, Archives of general psychiatry.

[45]  S. Lipton,et al.  Redox modulation of the NMDA receptor , 2000, Cellular and Molecular Life Sciences CMLS.

[46]  D Hell,et al.  Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.

[47]  R. Wise,et al.  Chemical Stimulation of the Ventral Hippocampus Elevates Nucleus Accumbens Dopamine by Activating Dopaminergic Neurons of the Ventral Tegmental Area , 2000, The Journal of Neuroscience.

[48]  A. Grace,et al.  Glutamatergic Afferents from the Hippocampus to the Nucleus Accumbens Regulate Activity of Ventral Tegmental Area Dopamine Neurons , 2001, The Journal of Neuroscience.

[49]  Myriam Bernaudin,et al.  Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? , 2001, Trends in Neurosciences.

[50]  A. Sampson,et al.  GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. , 2001, The American journal of psychiatry.

[51]  W H Wong,et al.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Muller,et al.  Tetrodotoxin-sensitive enhancement of inhibition in CA1 pyramidal neurones by nicotine , 2001, Neuroreport.

[53]  J. Lisman,et al.  Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine , 2001, Hippocampus.

[54]  H. Schröder,et al.  Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins , 2001, Journal of Chemical Neuroanatomy.

[55]  Kristin S. Cadenhead,et al.  Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia , 2001, Schizophrenia Research.

[56]  大沼 徹.  Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia : focus on GABA content,GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression , 2001 .

[57]  A. Sampson,et al.  Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. , 2002, Cerebral cortex.

[58]  R. V. Van Heertum,et al.  NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.

[59]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. , 2002, Nature Reviews Genetics.

[60]  C. McBain,et al.  Distinct NMDA Receptors Provide Differential Modes of Transmission at Mossy Fiber-Interneuron Synapses , 2002, Neuron.

[61]  S. Kapur,et al.  Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. , 2002, Archives of general psychiatry.

[62]  F. Benes,et al.  Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. , 2002, Archives of general psychiatry.

[63]  Raymond Dingledine,et al.  Control of Feedforward Dendritic Inhibition by NMDA Receptor-Dependent Spike Timing in Hippocampal Interneurons , 2002, The Journal of Neuroscience.

[64]  H. Nyman.  Neuropsychological function in schizophrenia , 2002, European Psychiatry.

[65]  Gavin P. Reynolds,et al.  A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia , 2002, Schizophrenia Research.

[66]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia (vol 99, pg 13675, 2002) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Kemp,et al.  Severe Impairment of NMDA Receptor Function in Mice Carrying Targeted Point Mutations in the Glycine Binding Site Results in Drug-Resistant Nonhabituating Hyperactivity , 2002, The Journal of Neuroscience.

[68]  D. Javitt,et al.  Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. , 2002, The American journal of psychiatry.

[69]  N. Mori,et al.  Unilateral auditory hallucinations in schizophrenia after damage to the right hippocampus , 2002, Schizophrenia Research.

[70]  S. Erhardt,et al.  Kynurenic acid and schizophrenia. , 2003, Advances in experimental medicine and biology.

[71]  Kenji Hashimoto,et al.  Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. , 2003, Archives of general psychiatry.

[72]  S. Snyder,et al.  d-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  R. Yuste,et al.  Ca2+ imaging of mouse neocortical interneurone dendrites: Contribution of Ca2+‐permeable AMPA and NMDA receptors to subthreshold Ca2+dynamics , 2003, The Journal of physiology.

[74]  R. Yuste,et al.  Ca 2 + imaging of mouse neocortical interneurone dendrites : Contribution of Ca 2 +-permeable AMPA and NMDA receptors to subthreshold Ca 2 + dynamics , 2003 .

[75]  Douglas L Falls,et al.  Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.

[76]  B. Morris,et al.  Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[77]  S. Christian,et al.  Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. , 2003, American journal of human genetics.

[78]  E. Gordon,et al.  Synchronous Gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia , 2003, Brain Research Reviews.

[79]  J. Coyle,et al.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia , 2004, Psychopharmacology.

[80]  Y. Minabe,et al.  Auditory hallucinations and cognitive impairment in a patient with a lesion restricted to the hippocampus , 2003, Schizophrenia Research.

[81]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[82]  J. Seamans,et al.  The principal features and mechanisms of dopamine modulation in the prefrontal cortex , 2004, Progress in Neurobiology.

[83]  Jill Harkavy-Friedman,et al.  Resting neural activity distinguishes subgroups of schizophrenia patients , 2004, Biological Psychiatry.

[84]  Bita Moghaddam,et al.  NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[85]  P. Skudlarski,et al.  Nicotine effects on brain function and functional connectivity in schizophrenia , 2004, Biological Psychiatry.

[86]  H. Meltzer,et al.  Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. , 2004, The international journal of neuropsychopharmacology.

[87]  Takahisa Taguchi,et al.  Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. , 2004, Human molecular genetics.

[88]  E. Castrén,et al.  Effects of NMDA-Receptor Antagonist Treatment on c-fos Expression in Rat Brain Areas Implicated in Schizophrenia , 2004, Cellular and Molecular Neurobiology.

[89]  D. Senkowski,et al.  Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing , 2004, Clinical Neurophysiology.

[90]  Zhen Yan,et al.  Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C‐dependent mechanism in pyramidal neurones of rat prefrontal cortex , 2004, The Journal of physiology.

[91]  T. Woo,et al.  Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. , 2004, Archives of general psychiatry.

[92]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[93]  A. Becker,et al.  Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia , 2004, Neuroscience.

[94]  Raquel E Gur,et al.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. , 2004, The Journal of clinical investigation.

[95]  Michael J Owen,et al.  Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? , 2005, Schizophrenia bulletin.

[96]  A. Addington,et al.  GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss , 2005, Molecular Psychiatry.

[97]  D. Javitt,et al.  Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. , 2005, The American journal of psychiatry.

[98]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[99]  G. Kirov,et al.  Finding schizophrenia genes. , 2005, The Journal of clinical investigation.

[100]  T. Murray,et al.  Role of α7-nicotinic acetylcholine receptors in tetanic stimulation-induced γ oscillations in rat hippocampal slices , 2005, Neuropharmacology.

[101]  A. Addington,et al.  Dysbindin (DTNBP1, 6p22.3) is Associated with Childhood-Onset Psychosis and Endophenotypes Measured by the Premorbid Adjustment Scale (PAS) , 2005, Journal of autism and developmental disorders.

[102]  P. Mortensen,et al.  Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study , 2005, BMJ : British Medical Journal.

[103]  J. Lisman.  The theta/gamma discrete phase code occuring during the hippocampal phase precession may be a more general brain coding scheme , 2005, Hippocampus.

[104]  D. Javitt,et al.  Early-stage visual processing and cortical amplification deficits in schizophrenia. , 2005, Archives of general psychiatry.

[105]  Bita Moghaddam,et al.  Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. , 2005, Journal of neurophysiology.

[106]  A. Marty,et al.  Developmental Changes in Parvalbumin Regulate Presynaptic Ca2+ Signaling , 2005, The Journal of Neuroscience.

[107]  F. Benes,et al.  Regulation of synaptic plasticity in a schizophrenia model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[109]  Veena Kumari,et al.  Nicotine use in schizophrenia: The self medication hypotheses , 2005, Neuroscience & Biobehavioral Reviews.

[110]  Stephan Heckers,et al.  Sustained activation of the hippocampus in response to fearful faces in schizophrenia , 2005, Biological Psychiatry.

[111]  A. Lahti,et al.  The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers , 2005, Psychopharmacology.

[112]  K. Hashimoto,et al.  Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[113]  陳柏維,et al.  Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2005 .

[114]  J. Lisman,et al.  The Hippocampal-VTA Loop: Controlling the Entry of Information into Long-Term Memory , 2005, Neuron.

[115]  P. Somogyi,et al.  Defined types of cortical interneurone structure space and spike timing in the hippocampus , 2005, The Journal of physiology.

[116]  K. Davis,et al.  Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia , 2005, Synapse.

[117]  S. Purcell,et al.  Support for involvement of neuregulin 1 in schizophrenia pathophysiology , 2005, Molecular Psychiatry.

[118]  H. Tanila,et al.  Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man , 2005, Psychopharmacology.

[119]  Fiona E. N. LeBeau,et al.  Region-Specific Reduction in Entorhinal Gamma Oscillations and Parvalbumin-Immunoreactive Neurons in Animal Models of Psychiatric Illness , 2006, The Journal of Neuroscience.

[120]  F. McMahon,et al.  G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis , 2006, Biological Psychiatry.

[121]  Y. Yanagawa,et al.  Major Effects of Sensory Experiences on the Neocortical Inhibitory Circuits , 2006, The Journal of Neuroscience.

[122]  T. Bártfai,et al.  A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons , 2006, The Journal of Neuroscience.

[123]  G. Fischbach,et al.  An acute effect of neuregulin 1 beta to suppress alpha 7-containing nicotinic acetylcholine receptors in hippocampal interneurons. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[124]  N. Bunzeck,et al.  Absolute Coding of Stimulus Novelty in the Human Substantia Nigra/VTA , 2006, Neuron.

[125]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[126]  Michael J. Gutnick,et al.  NMDA Receptors in Layer 4 Spiny Stellate Cells of the Mouse Barrel Cortex Contain the NR2C Subunit , 2006, The Journal of Neuroscience.

[127]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[128]  A. Carlsson.  The Neurochemical Circuitry of Schizophrenia , 2006, Pharmacopsychiatry.

[129]  H Ujike,et al.  Serine racemase binds to PICK1: potential relevance to schizophrenia , 2006, Molecular Psychiatry.

[130]  R. Freedman,et al.  Genetics of Chromosome 15q13-q14 in Schizophrenia , 2006, Biological Psychiatry.

[131]  A genetic variant of the serine racemase gene is associated with schizophrenia , 2006 .

[132]  David A Lewis,et al.  Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.

[133]  Paul J. Harrison,et al.  Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors , 2006, Molecular Psychiatry.

[134]  Anthony A. Grace,et al.  A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia , 2006, Biological Psychiatry.

[135]  J. Wagner,et al.  Dopamine-Mediated Disinhibition in the CA1 Region of Rat Hippocampus via D3 Receptor Activation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[136]  D. Purpura,et al.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders , 2007, Nature Reviews Neuroscience.

[137]  J. Suvisaari,et al.  Lifetime prevalence of psychotic and bipolar I disorders in a general population. , 2007, Archives of general psychiatry.

[138]  R. Panizzutti,et al.  A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia , 2007, Schizophrenia Research.

[139]  Birgit Funke,et al.  DTNBP1 genotype influences cognitive decline in schizophrenia , 2007, Schizophrenia Research.

[140]  John J. Foxe,et al.  The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents. , 2007, The American journal of psychiatry.

[141]  P. Jonas,et al.  Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks , 2007, Nature Reviews Neuroscience.

[142]  A. Grace,et al.  Aberrant Hippocampal Activity Underlies the Dopamine Dysregulation in an Animal Model of Schizophrenia , 2007, The Journal of Neuroscience.

[143]  T. Shinkai,et al.  Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia , 2007, NeuroMolecular Medicine.

[144]  T. Gao,et al.  Neuregulin-1 Enhances Depolarization-Induced GABA Release , 2007, Neuron.

[145]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[146]  K. Newell,et al.  Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[147]  Benjamin W. H. Lim,et al.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.

[148]  John J. Foxe,et al.  Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. , 2007, Brain : a journal of neurology.

[149]  F. Sharp,et al.  Psychosis: Atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty? , 2007, Epilepsy & Behavior.

[150]  Roberto Malinow,et al.  The Neuregulin-1 Receptor ErbB4 Controls Glutamatergic Synapse Maturation and Plasticity , 2007, Neuron.

[151]  Kari Stefansson,et al.  Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/− Knock-Outs Compared with Wild-Type Mice , 2007, The Journal of Neuroscience.

[152]  R. Freedman,et al.  Schizophrenia and the alpha7 nicotinic acetylcholine receptor. , 2007, International review of neurobiology.

[153]  M. Gill,et al.  Evidence for association and epistasis at the DAOA/G30 and D‐amino acid oxidase loci in an Irish schizophrenia sample , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[154]  Fiona E. N. LeBeau,et al.  Recruitment of Parvalbumin-Positive Interneurons Determines Hippocampal Function and Associated Behavior , 2007, Neuron.

[155]  D. Kullmann,et al.  Cholinergic Axons Modulate GABAergic Signaling among Hippocampal Interneurons via Postsynaptic α7 Nicotinic Receptors , 2007, The Journal of Neuroscience.

[156]  Kevin L Quick,et al.  Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase , 2007, Science.

[157]  D. Goff,et al.  The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls , 2008, Neuropsychopharmacology.